Complete immunisation schedules
All information is correct at the time of publication.
Date published: 1 January 2026
The childhood immunisation schedule in Wales changed on 1 January 2026
See the schedule below, or for more information about these changes and to check your child’s eligibility go to: Changes to the childhood immunisation schedule.
The complete routine immunisation schedule for Wales from January 2026
| Age due | Diseases protected against | Vaccine | Name | Usual site |
|---|---|---|---|---|
| 8 weeks old |
Diphtheria, tetanus, pertussis (whooping cough), polio, haemophilus influenzae type b (Hib) and hepatitis B |
DTaP/IPV/Hib/ HepB (6-in-1) | Infanrix hexa® or Vaxelis® | Thigh |
| 8 weeks old | Meningococcal group B (MenB) | MenB | Bexsero® | Thigh |
| 8 weeks old | Rotavirus gastroenteritis | Rotavirus | Rotarix® | By mouth |
| 12 weeks old | Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | DTaP/IPV/Hib/ HepB | Infanrix hexa® or Vaxelis® | Thigh |
| 12 weeks old | Meningococcal group B (MenB) | MenB | Bexero® | Thigh |
| 12 weeks old | Rotavirus gastroenteritis | Rotavirus | Rotarix® | By mouth |
| 16 weeks old | Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | DTaP/IPV/Hib/ HepB | Infanrix hexa®or Vaxelis® | Thigh |
| 16 weeks old | Pneumococcal | PCV 13 | Prevenar 13®1 | Thigh |
| 12 months old | Pneumococcal | PCV 13 | Prevenar 13®1 | Upper arm/ thigh |
| 12 months old | Meningococcal group B (MenB) | Men B | Bexero® | Upper arm/ thigh |
| 12 months old | Measles, mumps and rubella | MMR | ProQuad® or Priorix-Tetra® | Upper arm/ thigh |
| 18 months old |
Born before 1 July 2024: No appointment Born on or after 1 July 2024: Measles, mumps and rubella |
MMR | ProQuad® or Priorix-Tetra® | Upper arm/thigh |
| 18 months old |
Born before 1 July 2024: No appointment Born on or after 1 July 2024: Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B |
DTaP/IPV/Hib/HepB (6-in-1) | Infanrix hexa® or Vaxelis® | Upper arm/thigh |
| 22 and 3 years old and all school aged children | Influenza (annually from September) | Live attenuated influenza vaccine | Fluenz®3 | Both nostrils |
| 3 years 4 months old | Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | dTaP/IPV (4-in-1) | Boostrix-IPV® or Repevax® | Upper arm |
| 3 years 4 months old |
Born before 1 January 2025: Measles, mumps and rubella Born on or after 1 January 2025: No MMRV vaccine |
MMRV | ProQuad® or Priorix-Tetra® | Upper arm |
|
School year 8 (12 to 13 year olds) |
Cancers and genital warts caused by specific human papillomavirus (HPV) types | HPV4 (one dose) | Gardasil 9® | Upper arm |
|
School year 9 (13 and 14 year olds) |
Tetanus, diphtheria and polio | Td/IPV (3-in-1) (check MMR status) | Revaxis® | Upper arm |
|
School year 9 (13 and 14 year olds) |
Meningococcal groups A, C, W and Y | MenACWY | Nimenrix® or MenQuadfi® | Upper arm |
| 65 years of age and older | Influenza (annually) | Inactivated influenza vaccine |
Adjuvanted trivalent influenza vaccine (aTIV) or Cell-based trivalent influenza vaccine (TIVc)5 |
Upper arm |
| 65 years of age | Pneumococcal | PPV23 or PCV206 | Pneumovax 23® or Prevenar 20® | Upper arm |
|
65 years old and 70 to 79 years old (plus people from age 18 with severe immunosuppression)7 |
Shingles | Shingles | Shingrix® | Upper arm |
| 75 years | Respiratory Syncytial Virus (RSV) | RSV | Abrysvo® | Upper arm |
1 Refer to the Green Book Chapter: Pneumococcal – table 25.3 (external site) for babies with asplenia, splenic dysfunction, complement disorder or severely immunocompromised.
2 Children must be 2 years old by 31 August to receive influenza vaccine in the routine programme in autumn/winter
3 If Fluenz® is unsuitable, use inactivated flu vaccine.
4 Check the relevant chapter of the Green Book for individuals requiring a 3-dose schedule.
5 Only use TIVc if no aTIV stock is available or if aTIV is unsuitable.
6 PCV20 is expected to replace PPV23 in early 2026.
Selective immunisation programmes
| Target group | Age and schedule | Disease | Vaccines |
|---|---|---|---|
| Babies born to hepatitis B infected mothers | At birth and 1 month old1 | Hepatitis B |
Hepatitis B vaccines (Engerix B® / HBvaxPRO®) |
| Infants in areas of the country with TB incidence >= 40/100,000 | From birth | Tuberculosis | BCG® |
| Infants with a parent or grandparent born in a high incidence country2 |
From birth |
Tuberculosis |
BCG® |
| People in a risk group for influenza3 | From 6 months to 64 years | Influenza | Age-appropriate flu vaccine3 |
| Pregnant women | From 16 weeks of pregnancy | Pertussis |
Tdap (ADACEL®) If ADACEL® is unavailable or contraindicated, administer dTaP/IPV (Boostrix-IPV® or Repevax®) |
| Pregnant women | From 28 weeks of pregnancy | Respiratory syncytial virus (RSV) | Abrysvo® |
| Pregnant women | At any stage in pregnancy during the flu season | Influenza | Recommended inactivated flu vaccine3 |
| Gay, bisexual and other men who have sex with men |
45 years of age and under4 |
HPV4 | Gardasil 9® |
| People at increased risk of mpox | Based on risk | Mpox | Imvanex® |
| People at increased risk of gonorrhoea | Based on risk | Gonorrhoea | Bexsero® |
1 In addition to hexavalent vaccine (Infanrix hexa or Vaxelis) given at 8, 12, 16 weeks and 18 months. Take blood for HBsAg to exclude infection at 12 to 18 months.
2 Where the annual incidence of TB is >= 40/100,000 see the WHO country profile (external site).
3 Refer to annual flu Welsh Health Circular (external site) for eligibility criteria and vaccine recommendations
4 Check the Green Book Chapter: HPV (external site) for individuals requiring a 1, 2 or 3 dose schedule.
5A sexual health clinician will assess individuals attending the sexual health clinic and advise vaccination if required
Additional vaccines for individuals with underlying medical conditions1
| Medical condition | Diseases protected against | Vaccines required2 |
|---|---|---|
| Asplenia, splenic dysfunction or complement disorder (Including people with coeliac disease who have splenic dysfunction, and all haemoglobinopathies such as homozygous sickle cell disease) |
Meningococcal groups A, B, C, W and Y Pneumococcal Influenza |
MenACWY MenB PCV13® or PCV20 (up to two years of age)3 PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 |
| Cochlear implants, cerebrospinal fluid leaks | Pneumococcal | PPV23 or PCV20 (from two years of age)4 |
|
Chronic respiratory and heart conditions (such as moderate to severe asthma, chronic pulmonary disease, and heart failure) |
Pneumococcal Influenza |
PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 |
|
Chronic neurological conditions (such as Parkinson’s or motor neurone disease, or learning disability) |
Pneumococcal (only if the individual is also at increased risk of aspiration) Influenza |
PPV23 (from two years of age)4 Annual flu vaccine5 |
| Diabetes |
Pneumococcal Influenza |
PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 |
|
Chronic kidney disease (CKD) (including haemodialysis) |
Pneumococcal (stage 4 and 5 CKD) Influenza (stage 3, 4 and 5 CKD) Hepatitis B (stage 4 and 5 CKD) |
PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 Hepatitis B |
| Chronic liver conditions |
Pneumococcal Influenza Hepatitis A & B |
PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 Hepatitis A & Hepatitis B |
| Haemophilia | Hepatitis A & B | Hepatitis A & B |
| Immunosuppression due to disease or treatment |
Pneumococcal Influenza Shingles |
PCV13 or PCV20 (up to two years of age)3 PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 Shingrix (aged 18 years and over) |
1 The list is not exhaustive. Other vaccines may be recommended for certain individuals.
2 Check relevant chapter of the Green Book (external site) for specific schedule and for further detail.
3 See table 25.3 – Summary of vaccine doses for at-risk patients in the Green Book, Chapter 25 about pneumococcal on the UK Government website (external site) for further information.
4 Refer to the Green Book Chapter: Pneumococcal (external site) for detailed guidance on vaccine recommendations for this clinical risk group. PCV20 is expected to replace PPV23 in late 2025 or early 2026.
5 From six months of age.
6 Consider annual influenza vaccination for household members and those who care for people with these conditions.